8 0 0 VOLUME 22 | NUMBER 7 | JULY 2016 nature medicine l e t t e r S Type 2 diabetes (T2D) is among the most common and costly disorders worldwide 1 . The goal of current medical management for T2D is to transiently ameliorate hyperglycemia through daily dosing of one or more antidiabetic drugs. Hypoglycemia and weight gain are common side effects of therapy, and sustained disease remission is not obtainable with nonsurgical approaches. On the basis of the potent glucose-lowering response elicited by activation of brain fibroblast growth factor (FGF) receptors 2-4 , we explored the antidiabetic efficacy of centrally administered FGF1, which, unlike other FGF peptides, activates all FGF receptor subtypes 5 . We report that a single intracerebroventricular injection of FGF1 at a dose one-tenth of that needed for antidiabetic efficacy following peripheral injection induces sustained diabetes remission in both mouse and rat models of T2D. This antidiabetic effect is not secondary to weight loss, does not increase the risk of hypoglycemia, and involves a novel and incompletely understood mechanism for increasing glucose clearance from the bloodstream. We conclude that the brain has an inherent potential to induce diabetes remission and that brain FGF receptors are potential pharmacological targets for achieving this goal.
l e t t e r S Type 2 diabetes (T2D) is among the most common and costly disorders worldwide 1 . The goal of current medical management for T2D is to transiently ameliorate hyperglycemia through daily dosing of one or more antidiabetic drugs. Hypoglycemia and weight gain are common side effects of therapy, and sustained disease remission is not obtainable with nonsurgical approaches. On the basis of the potent glucose-lowering response elicited by activation of brain fibroblast growth factor (FGF) receptors [2] [3] [4] , we explored the antidiabetic efficacy of centrally administered FGF1, which, unlike other FGF peptides, activates all FGF receptor subtypes 5 . We report that a single intracerebroventricular injection of FGF1 at a dose one-tenth of that needed for antidiabetic efficacy following peripheral injection induces sustained diabetes remission in both mouse and rat models of T2D. This antidiabetic effect is not secondary to weight loss, does not increase the risk of hypoglycemia, and involves a novel and incompletely understood mechanism for increasing glucose clearance from the bloodstream. We conclude that the brain has an inherent potential to induce diabetes remission and that brain FGF receptors are potential pharmacological targets for achieving this goal.
Growing evidence points to the brain as a potential target for the treatment of T2D 6, 7 . In rodent models of T2D, hyperglycemia can be ameliorated transiently by either systemic or intracerebroventricular (i.c.v.) administration of FGF19 (refs. [2] [3] [4] 8) or FGF21 (ref. 9) . Unlike these peptide hormones, which bind to and activate a limited subset of FGF receptors (FGFRs) via an interaction that requires the co-receptor klotho (also referred to as β-Klotho; encoded by KLB), the tissue growth factor FGF1 binds to and activates all known FGFR isoforms without the need for β-Klotho 5 . Moreover, the lowering of glucose levels elicited by systemic administration of FGF1 is of longer duration (up to 42 h) 10 than that elicited by either FGF19 (ref. 2) or FGF21 (ref. 9) . FGF1 is synthesized by neurons, astrocytes, and ependymal cells 11, 12 , and administration of FGF1 directly into the brain can enhance learning and memory 12 , reduce food intake 13 , and limit damage associated with ischemic stroke or neurodegenerative disease 14, 15 . In addition, a physiological role for FGF1 in glucose homeostasis is implied by the development of diabetes in mice lacking FGF1 that are challenged with a high-fat diet (HFD) 16 .
We therefore hypothesized that, similarly to FGF19 and FGF21, FGF1 action in the brain promotes glucose lowering in rodent models of T2D and that-on the basis of its relatively prolonged antidiabetic action following systemic administration-glucose lowering induced by i.c.v. administration of FGF1 (hereafter referred to as i.c.v. FGF1) would be long lived relative to that by other FGF peptides. To test this hypothesis, we monitored blood glucose levels following a single injection of recombinant mouse FGF1 (mFGF1) into the lateral ventricle of leptin-deficient ob/ob mice (a genetic model of T2D) at a dose (3 µg) one-tenth of that needed for antidiabetic efficacy following peripheral injection 10 . As predicted, we observed a ~25% decline in fasting blood glucose levels 6 h after i.c.v. mFGF1 (Fig. 1a) . Although modest, this effect cannot be explained by either reduced food intake (because food was not available during this time) or by leakage from the brain to the periphery, as subcutaneous (s.c.) administration of the same dose of FGF1 was without effect (Fig. 1b) .
To assess the duration of this glucose-lowering effect, we monitored blood glucose levels of both fasting and ad libitum (ad-lib)-fed ob/ob mice over time after a single i.c.v. injection of mFGF1. We found that blood glucose levels were fully normalized 7 d later (Fig. 1c,d ) and remained within the normal range (<200 mg/dl) for the next 17 weeks (having concluded that sustained diabetes remission had been achieved, the study was terminated after a total duration of 18 weeks) (Fig. 1c,d ). This sustained glucose-lowering effect of i.c.v. FGF1 was not associated with changes in levels of either insulin or glucagon in blood (Supplementary Fig. 1a ).
Central injection of fibroblast growth factor 1 induces sustained remission of diabetic hyperglycemia in rodents Although food intake and body weight were also reduced by i.c.v. mFGF1 in these mice, the effect was transient, such that the pronounced improvement of glycemia persisted for months even though food intake, body weight, and fat mass returned to normal (Fig. 1e) . This finding suggests, but does not establish, that diabetes remission induced by central administration of FGF1 is weight-loss independent. To more directly test this hypothesis, two additional groups of ob/ob mice were monitored after receiving a single i.c.v. injection of saline vehicle (veh). One of these groups was allowed to feed ad-lib, whereas the other was pair-fed to the amount of food consumed by the ob/ob mice that had received i.c.v. FGF1. Although blood glucose values declined in the pair-fed group relative to that in the ad-lib-fed mice, the effect was both modest and transient, and did not reach statistical significance (Fig. 1f) . Therefore, sustained diabetes remission that is induced by the central action of FGF1 cannot be explained by reduced food intake or decreased body weight.
To assess the reproducibility of these findings, we subjected three additional groups of diabetic ob/ob mice to a single i.c.v. injection of veh, recombinant human FGF1 (hFGF1), or mFGF1. Although the onset of glucose lowering in response to hFGF1 was delayed by 24 h, sustained diabetes remission was nevertheless observed following a single i.c.v. injection of either peptide (Fig. 2a) . In addition, prolonged glucose lowering accompanied by a transient reduction of food intake and body weight were observed irrespective of whether mFGF1 (3 µg) was injected into the lateral ventricle (Fig. 1d,e) or the third ventricle of the brain (Supplementary Fig. 1b) . Hypoglycemia was not elicited by i.c.v. FGF1 in either ob/ob mice (Fig. 2a) or in lean, wild-type (WT) controls, irrespective of whether they were fed a standard chow (Fig. 2b) or a HFD (Fig. 2c) . Although this ability to ameliorate hyperglycemia without the risk of hypoglycemia is shared by both systemic administration of a ~10-fold higher dose of mFGF1 (0.5 mg per kg body weight (mg/kg) by s.c. injection; Fig. 2d ) and central administration of the same dose of recombinant human FGF19 (hFGF19) (3 µg by i.c.v. injection; Fig. 2e ), neither intervention elicits persistent glucose lowering. Sustained diabetes remission induced by the central action of FGF1, therefore, involves mechanisms distinct from those engaged by either systemic FGF1 or i.c.v. FGF19 when administered at doses with comparable short-term glucose-lowering efficacy.
On the basis of the evidence that i.c.v. FGF1 reduces blood glucose levels and suppresses the hypothalamic-pituitary-adrenal (HPA) axis in rats with severe diabetic ketoacidosis 17 , we measured plasma corticosterone levels at a fixed time of day (in mid-light cycle, between 14:00 and 16:00 h, following a 6-h fast) 6 h after administration of either mFGF1 (3 µg) or veh into either the lateral ventricle or the third ventricle of ob/ob mice. Plasma corticosterone levels were not reduced by FGF1 (irrespective of the route of i.c.v. delivery; Supplementary  Fig. 2a,b ) in these mice nor was such an effect observed in ob/ob mice with sustained FGF1-induced diabetes remission (again, measured during mid-light cycle following a 6-h fast), despite their much lower blood glucose levels (Supplementary Fig. 2c ). Diabetes remission induced by i.c.v. FGF1, therefore, cannot be attributed to HPA axis suppression.
To investigate whether sustained diabetes remission induced by centrally administered FGF1 in ob/ob mice occurs in other mouse models of T2D, we repeated the experiment in leptin-receptor-deficient db/db mice, another genetic model of T2D (Fig. 2f) . We also used the combination of diet-induced obesity (DIO) with a low dose of the beta cell toxin streptozotocin (DIO-LD STZ) in WT mice to model the combination of insulin resistance and pancreatic beta cell dysfunction of human T2D (Fig. 2g) . Our finding-that sustained glucose lowering was induced by i.c.v. mFGF1 in each of these mouse models-demonstrates that remission of T2D that is induced by the central action of FGF1 is not limited to ob/ob mice. As expected, both food intake and body weight were also reduced following i.c.v. FGF1 in these mouse models (Supplementary Fig. 3a,b) , and as in ob/ob mice (Supplementary Fig. 3c ), these effects were transient such that pronounced glucose lowering persisted after body weight had returned to control values (Fig. 2f,g ).
To determine whether FGF1-induced diabetes remission is achievable in a different species, we administered either the same dose (3 µg by i.c.v. injection) of recombinant rat FGF1 (rFGF1) or veh to adult male leptin-receptor-deficient Zucker diabetic fatty (ZDF) rats. npg l e t t e r S 8 0 2 VOLUME 22 | NUMBER 7 | JULY 2016 nature medicine Consistent with our findings in mice, diabetes remission lasting >4 weeks was induced by a single i.c.v. injection of rFGF1 in these rats and, once again, hypoglycemia was not observed (Fig. 2h) , although food intake and body weight were reduced, as expected ( Supplementary Fig. 3d ). Because pronounced glucose lowering in ZDF rats persisted even after food intake, body weight, and fat mass had returned to control values ( Fig. 2h and Supplementary Fig. 3d) , we conclude that, similarly to our observations with diabetic mice, i.c.v. FGF1 induces weight-loss-independent diabetes remission in a rat model of T2D.
To investigate the peripheral mechanisms that underlie the diabetes remission induced by i.c.v. mFGF1, we first measured the rate of plasma glucose clearance in the basal state. We found that despite a ~39% reduction of fasting blood glucose values 1 week after i.c.v. mFGF1 (3 µg) in ob/ob mice (Fig. 3a) , there was no difference in the basal glucose turnover rate (GTR; which, at steady-state, equals the rates of both glucose production and glucose disposal) (Fig. 3b) . Implied in this observation is an increased peripheral glucose clearance rate (a measure of the efficiency of glucose removal from the circulation) 18 , as the rate of disposal of glucose increases as a function of its plasma level. Accordingly, the basal glucose clearance rate was increased twofold in mice receiving i.c.v. mFGF1 as compared to that in veh-treated mice (Fig. 3b) .
To determine whether this increase in basal glucose clearance resulted from an increase in insulin sensitivity (measured as the insulin sensitivity index, S I ), insulin secretion (measured as the acute insulin response to glucose, AIR g ), or insulin-independent glucose disposal (measured as glucose effectiveness, S g ), we performed a 'frequently sampled intravenous glucose tolerance test' (FSIGT) followed by minimal-model analysis of the blood glucose and plasma insulin data (a method validated in humans 19 , primates 20 , dogs 21 , and rodents 2, 22, 23 ) in the same cohort of ob/ob mice (Fig. 3a) . Although a trend toward improved glucose tolerance was observed in mice that had received i.c.v. mFGF1, the effect was not statistically significant after correcting for the difference in basal glucose levels (measured as 'delta area under the glucose curve' (AUC); Fig. 3a) . A tendency for increased glucose-induced insulin secretion (AIR g ) was also observed in the group that had received i.c.v. FGF1, but this effect did not achieve statistical significance, nor did increases in either S I or S G (Fig. 3a,c) . Sustained diabetes remission induced by the central action of FGF1, therefore, involves a novel mechanism that is characterized by increased peripheral glucose clearance in the basal state, with no change in basal hepatic glucose production, glucose tolerance, or any of the three determinants of glucose tolerance (S I , AIR g , and S G ).
Relative to control mice that received i.c.v. veh, both hepatic glycogen content and hepatic expression of genes encoding the key glucoregulatory enzymes glucokinase (Gck), pyruvate kinase liver and red blood cell (Pklr), and glycogen synthase 2 (Gys2) were increased in ob/ob mice 1 week following i.c.v. mFGF1 (Fig. 3d) . Combined with an increase of basal plasma lactate levels (Fig. 3d) , which is suggestive of increased intrahepatic glycolysis 2,24,25 , diabetes remission induced by i.c.v. FGF1 seems to involve increased hepatic glucose uptake (HGU) with subsequent increases of both glycogen synthesis and glycolysis. In contrast, the hepatic expression of genes encoding the gluconeogenic enzymes phosphoenolpyruvate carboxykinase 1, cytosolic (Pck1) and glucose-6-phosphatase, catalytic (G6pc) was not altered by i.c.v. mFGF1 (Fig. 3d) , consistent with the absence of any effect on basal GTR.
To determine whether tissues other than the liver contribute to the FGF1-mediated increase in basal glucose clearance, we collected tissues from ob/ob mice after a bolus intravenous (i.v.) infusion of radiolabeled 2-deoxyglucose 1 week after a single i.c.v. injection of mFGF1 (3 µg) or veh. Mixed-model analysis revealed that the rate of glucose clearance (K g ) into skeletal muscle-but not heart, adipose tissue, or brain-was increased following i.c.v. FGF1 (after adjusting for the four skeletal muscle types sampled; Online Methods) (Fig. 3e) . Thus, diabetes remission induced by i.c.v. FGF1 seems to involve increases in basal glucose clearance into both liver and skeletal muscle, but not into other tissues. Our finding that i.c.v. FGF1 did not increase glucose uptake into brown adipose tissue (BAT) suggests that activation of this thermogenic tissue does not participate in FGF1-induced diabetes remission. As a further test of this hypothesis, we measured the level of mRNA encoding the mitochondrial proton carrier uncoupling protein 1 (Ucp1) in BAT from ob/ob mice that received i.c.v. mFGF1 or veh. Our finding that Ucp1 mRNA levels in BAT were not increased in animals that received i.c.v. FGF1 (Supplementary Fig. 4a ) further suggests that BAT thermogenesis does not contribute to diabetes remission induced by the action of FGF1 in the brain. Similarly, diabetes remission induced by i.c.v. FGF1 was not associated with reduced plasma levels of triglycerides, cholesterol, or non-esterified free fatty acids (NEFA) in either ob/ob or db/db mice ( Supplementary Fig. 4b,c) . Unlike the lack of glycemic regulation that is characteristic of uncontrolled type 1 diabetes 26 , the pathogenesis of T2D seems to involve the regulation of glycemia at an elevated level 27 . This distinction provides a useful context within which to consider our finding that although i.c.v. FGF1 worked well in both mouse and rat models of T2D with moderate hyperglycemia, it was ineffective in mice with more severe, uncontrolled hyperglycemia (blood glucose >300 mg/dl). This observation applies not only to db/db mice and DIO WT mice that received a high dose of STZ (Supplementary Fig. 5a,b) but also to ob/ob mice that were crossed onto the diabetogenic BTBR background (Supplementary Fig. 5c ).
One potential explanation for this outcome is that FGF1-mediated glucose lowering requires an intact insulin signal-i.e., intact basal insulin action is permissive for diabetes remission induced by centrally administered FGF1. To formally test this hypothesis, we administered S961, an antagonist of the high-affinity insulin receptor (IR) 28 , to DIO WT mice as a continuous s.c. infusion at a dose (29 nmol/week) designed to achieve the moderately elevated blood glucose levels that are characteristic of FGF1-responsive ob/ob mice (on the C57BL/6J background; Fig. 1d ). Although we observed the expected, transient reduction of food intake and body weight following i.c.v. mFGF1 in S961-treated mice (Supplementary Fig. 5d ), glucose lowering did not occur (Supplementary Fig. 5d ). Thus, intact insulin signaling seems to be required for diabetes remission induced by the central action of FGF1.
In hepatocytes, the glucose-lowering action of insulin depends on inactivation of the transcription factor FOXO1 (ref. 29) , and in mice with deficient hepatic insulin signaling, increased FOXO1 signaling potently inhibits HGU 30, 31 . These observations raise the possibility that the activation of hepatic FOXO1 induced by insulin receptor blockade underlies the observed resistance to FGF1-mediated glucose lowering. To test this hypothesis, we studied the effect of i.c.v. mFGF1 in mice with a liver-specific deletion of the genes encoding FOXO1 (Foxo1) and the insulin receptor (Insr) (hereafter referred to as liver IR-FOXO1 double-knockout, or LIRFKO, mice 30 ) and in which hyperglycemia was induced by systemic S961 administration. As expected, IR blockade induced by S961 did not impair the ability of i.c.v. FGF1 to reduce food intake and body weight (Supplementary Fig. 6a,b) ; however, hyperglycemia elicited by systemic IR blockade was not ameliorated by central administration of mFGF1 in either LIRFKO mice or their controls (Supplementary Fig. 6a,b) . Resistance to FGF1-mediated glucose lowering that is conferred by IR blockade therefore involves mechanisms in addition to that of hepatic FOXO1 activation.
Tanycytes are cells that line the third ventricle adjacently to the mediobasal hypothalamus (MBH). Because they are responsive to both glucose and FGF1 (refs. 32,33) , tanycytes could potentially be mediators of FGF1-induced diabetes remission. To determine whether the response of these cells to FGF1 (which induces sustained diabetes remission) differs from that elicited by FGF19 (which does not induce diabetes remission), we used immunohistochemistry to detect c-FOS, a marker of cellular activation, 90 min following injection of veh, mFGF1, or hFGF19 into the lateral ventricle. Whereas i.c.v. FGF1 induced robust c-FOS expression in third-ventricular tanycytes, i.c.v. hFGF19 did not (Supplementary Fig. 7a,b) , raising the possibility of a functional link between the activation of third-ventricular tanycytes and diabetes remission induced by FGF1. Hypothalamic expression of heat shock protein 1 (HSPB1; also known as HSP25, the mouse homolog of human HSP27), a potent neuroprotectant molecule 34 , is highly responsive to FGF1 stimulation. Confirming a previous report 13 , we observed a marked increase of hypothalamic Hspb1 mRNA 6 h after i.c.v. injection of mFGF1 (3 µg) in nondiabetic control mice (Supplementary Fig. 7c ). To determine whether third-ventricular tanycytes are among the cells in which HSP25 is induced by mFGF1, we used whole-mount immunostaining of the wall of the third ventricle to detect expression of HSP25 24 h after a single i.c.v. injection of either mFGF1 or veh. Coupled with confocal microscopy, this method provides an en-face perspective not only of ependyma and tanycytes that line the ventricular surface but also of neurons and glia in hypothalamic parenchyma at a depth of up to 80 µm (ref. 35) . We found that i.c.v. mFGF1 induced robust expression of HSP25 in both a discrete band of tanycytes (Fig. 4a-c) in the posterior ventral aspect of the third-ventricular surface and in subependymal, stellate-shaped astrocytes (Fig. 4d) adjacent to the third ventricle. In contrast, expression of HSP25 was not detected in neurons nor was it detected in tanycytes or astrocytes in mice that had received i.c.v. veh (Fig. 4e-g ).
To investigate whether i.c.v. mFGF1 affects hypothalamic synaptic content, we quantified the level of synaptophysin 36, 37 , a synaptic marker, in hypothalamic extracts obtained 1 week after a single i.c.v. injection of mFGF1 or veh in ob/ob mice. Our finding of a 24% increase of hypothalamic synaptophysin content in FGF1-treated mice is suggestive of increased synaptic density in this brain area (Supplementary Fig. 7d) .
Except for certain bariatric surgical procedures, we are unaware of any intervention capable of inducing sustained remission of T2D in humans or rodents. Here we report that in multiple rodent models of T2D, a single i.c.v. dose of FGF1 restores blood glucose levels to the normal range in a manner that is sustained for weeks, is not associated with hypoglycemia, is not secondary to changes of energy balance or fat stores, and is apparently mediated by increased glucose clearance into both liver and skeletal muscle.
The liver's enormous capacity for glucose uptake contributes substantially to glucose clearance following a meal 38 . Although rising concentrations of glucose in the hepatic portal vein are the primary stimulus driving increased HGU, signals emanating from the brain have also been implicated 38 . Given our evidence linking increased HGU to FGF1-mediated glucose lowering, we speculate that diabetes remission induced by i.c.v. FGF1 involves an action on neurocircuits that normally enhance HGU after a meal. Increased glucose clearance into skeletal muscle also seemed to contribute to FGF1-mediated diabetes remission, and each of these effects occurred in the absence of increases of either basal insulin levels or glucose-induced insulin secretion. Because measures of insulin secretion were made at a time when blood glucose levels were lower in mFGF1-than in veh-treated mice, however, it remains possible that an effect of centrally administered FGF1 in enhancing insulin secretion was masked by the concurrent decrease of blood glucose levels. Combined with our finding that systemic IR blockade disrupts FGF1-mediated glucose lowering, additional investigation into insulin's role in FGF1-mediated diabetes remission is needed.
Although systemic FGF1 administration also has antidiabetic effects, it does not induce sustained diabetes remission 10 . This observation implies that the central nervous system (CNS) mechanisms that are activated by administration of FGF1 directly into the brain are not engaged by circulating FGF1. This possibility is strengthened by evidence that glucose lowering induced by systemic FGF1 requires FGFR1 signaling in adipose tissue 10 , a mechanism that is unlikely to explain the action of FGF1 in the brain.
A physiological role for hypothalamic FGF1 signaling in metabolic homeostasis was first suggested by evidence that FGF1 expressed in cells lining the third cerebral ventricle, which is adjacent to the MBH, is released locally following a meal 12 . Tanycytes (rather than ependymal cells) are the predominant cell type lining the third ventricle in the area of the MBH 35 . These cells have potential as candidate mediators of FGF1 action, as they send long, filamentous projections from the ventricular surface into adjacent hypothalamic parenchyma that can influence neuronal function, are responsive both to glucose 39, 40 and FGFs 33 , and are implicated as a source of hypothalamic neural progenitor cells 33 . In this context, our finding that third-ventricular tanycytes are robustly activated by i.c.v. mFGF1 (on the basis of the induction of c-FOS, a marker of cellular activation) but not by i.c.v. hFGF19 is of interest-given that glucose lowering by i.c.v. FGF1 is sustained, whereas that induced by i.c.v. FGF19 is not. Thus, the activation of these cells by FGF1 correlates with the ability of FGF peptides to induce diabetes remission. We further demonstrate that in response to i.c.v. FGF1, the potent neuroprotective protein HSP25 is induced in both third-ventricular tanycytes and an adjacent set of periventricular astrocytes 13 , but not in hypothalamic neurons. These observations justify additional investigation into the role of tanycytes in FGF1-mediated diabetes remission. A notable aspect of glucose lowering induced by i.c.v. FGF1 is that it occurs only in hyperglycemic but not in nondiabetic animals. To account both for this selectivity and for the sustained nature of its antidiabetic effect, we hypothesize that: (i) neurocircuits involved in glucose homeostasis are dysfunctional in T2D; (ii) this dysfunction contributes to hyperglycemia; and (iii) FGF1 ameliorates this dysfunction without impacting the same neurocircuits in nondiabetic animals. Accordingly, one might anticipate that central FGF1 administration in diabetic mice elicits structural changes in brain areas that are involved in glucoregulation. Although preliminary, our finding of an association between FGF1-induced diabetes remission and a modest increase in whole hypothalamic content of synaptophysin (a synaptic marker protein 36, 37 ) implies that either synaptogenesis was increased or that synaptic pruning was decreased (or both). Thus, additional studies to address these possibilities and to identify the hypothalamic areas involved are warranted.
In conclusion, we report that central FGF1 administration unmasks the brain's inherent capacity to induce sustained diabetes remission. This effect is elicited without the risk of hypoglycemia, in a manner that is truly weight-loss independent, via a novel peripheral mechanism that is characterized by increased glucose clearance into skeletal muscle and liver, and without the need for surgical revision of the gastrointestinal tract. The translational relevance of this discovery is heightened by the feasibility of therapeutic FGF1 delivery to the CNS via the intranasal route, which has been established in rodents 14, 15 . Translational studies are warranted to determine whether this type of strategy may be used to promote diabetes remission in humans.
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